"The maker of a much-debated drug for Lou Gehrig’s disease said Friday its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market...The latest company study showed that the drug did not slow the disease compared with a dummy treatment. The drug also failed to show improvement on any secondary measures, such as muscle strength."
https://apnews.com/article/als-drug-fda-relyvrio-study-patients-7340ef880306fbbadad720b8154b3605
#PrescriptionDrugs #FDA #ALS
Bích-Mây Nguyễn :verified: /
npub1pv…zxcs8
2024-03-11 21:57:01
Author Public Key
npub1pvedlj030w72mcryqx7qcuecq6pgy3mne5x9v6jhsppyy4sy5vas8zxcs8Seen on
wss://relay.noswhere.comPublished at
2024-03-11 21:57:01Event JSON
{
"id": "e8abdf17ad45e1c72effb5e8db074635a1c36026ae1ceed63805e5b3d66f0dcf",
"pubkey": "0b32dfc9f17bbcade06401bc0c73380682824773cd0c566a578042425604a33b",
"created_at": 1710194221,
"kind": 1,
"tags": [
[
"t",
"prescriptiondrugs"
],
[
"t",
"FDA"
],
[
"t",
"als"
],
[
"proxy",
"https://med-mastodon.com/users/bicmay/statuses/112079288482425047",
"activitypub"
]
],
"content": "\"The maker of a much-debated drug for Lou Gehrig’s disease said Friday its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market...The latest company study showed that the drug did not slow the disease compared with a dummy treatment. The drug also failed to show improvement on any secondary measures, such as muscle strength.\"\n\nhttps://apnews.com/article/als-drug-fda-relyvrio-study-patients-7340ef880306fbbadad720b8154b3605\n\n#PrescriptionDrugs #FDA #ALS",
"sig": "42dfb77dd8add7c9231c778c44f7f0c7bfb8fb1cfab395efb360182b4155e018b65d2341b8fa9c5df26954a87c331097b65a557161baac6229927955e525928c"
}